KR100860067B1 - 크루지페인 및 기타 시스테인 프로테아제의 억제제 - Google Patents

크루지페인 및 기타 시스테인 프로테아제의 억제제 Download PDF

Info

Publication number
KR100860067B1
KR100860067B1 KR1020037009524A KR20037009524A KR100860067B1 KR 100860067 B1 KR100860067 B1 KR 100860067B1 KR 1020037009524 A KR1020037009524 A KR 1020037009524A KR 20037009524 A KR20037009524 A KR 20037009524A KR 100860067 B1 KR100860067 B1 KR 100860067B1
Authority
KR
South Korea
Prior art keywords
oxo
hexahydrofuro
pyrrole
ethyl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020037009524A
Other languages
English (en)
Korean (ko)
Other versions
KR20030075161A (ko
Inventor
퀴벨마틴
Original Assignee
아무라 테라피틱스 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0101179A external-priority patent/GB0101179D0/en
Application filed by 아무라 테라피틱스 리미티드 filed Critical 아무라 테라피틱스 리미티드
Publication of KR20030075161A publication Critical patent/KR20030075161A/ko
Application granted granted Critical
Publication of KR100860067B1 publication Critical patent/KR100860067B1/ko
Assigned to 그뤼넨탈 게엠베하 reassignment 그뤼넨탈 게엠베하 권리의 전부이전등록 Assignors: 아무라 테라피틱스 리미티드
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020037009524A 2001-01-17 2002-01-17 크루지페인 및 기타 시스테인 프로테아제의 억제제 Expired - Fee Related KR100860067B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0101179A GB0101179D0 (en) 2001-01-17 2001-01-17 Biologically active compounds
GB0101179.0 2001-01-17
US27535901P 2001-03-13 2001-03-13
US60/275,359 2001-03-13
PCT/GB2002/000184 WO2002057270A1 (en) 2001-01-17 2002-01-17 Inhibitors of cruzipain and other cysteine proteases

Publications (2)

Publication Number Publication Date
KR20030075161A KR20030075161A (ko) 2003-09-22
KR100860067B1 true KR100860067B1 (ko) 2008-09-24

Family

ID=26245571

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020037009524A Expired - Fee Related KR100860067B1 (ko) 2001-01-17 2002-01-17 크루지페인 및 기타 시스테인 프로테아제의 억제제

Country Status (20)

Country Link
US (2) US7425562B2 (https=)
EP (1) EP1362052B1 (https=)
JP (1) JP4608183B2 (https=)
KR (1) KR100860067B1 (https=)
CN (1) CN1269822C (https=)
AT (1) ATE356130T1 (https=)
AU (1) AU2002219397B2 (https=)
BR (1) BR0206501A (https=)
CA (1) CA2436462C (https=)
CY (1) CY1106640T1 (https=)
DE (1) DE60218633T2 (https=)
DK (1) DK1362052T3 (https=)
ES (1) ES2281516T3 (https=)
IL (2) IL156774A0 (https=)
MX (1) MXPA03006224A (https=)
NO (1) NO328208B1 (https=)
NZ (1) NZ526913A (https=)
PT (1) PT1362052E (https=)
RU (1) RU2329266C2 (https=)
WO (1) WO2002057270A1 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7030116B2 (en) 2000-12-22 2006-04-18 Aventis Pharmaceuticals Inc. Compounds and compositions as cathepsin inhibitors
JP2004523506A (ja) 2000-12-22 2004-08-05 アクシス・ファーマシューティカルズ・インコーポレイテッド カテプシン阻害剤としての新規な化合物と組成物
EP1436255A1 (en) 2001-09-14 2004-07-14 Aventis Pharmaceuticals, Inc. Novel compounds and compositions as cathepsin inhibitors
YU34604A (sh) 2001-11-14 2006-08-17 Aventis Pharmaceuticals Inc. Oligopeptidi kao inhibitori katepsina s i kompozicije koje ih sadrže
DE60326473D1 (en) * 2002-07-16 2009-04-16 Amura Therapeutics Ltd Pyrrolderivate als hemmstoffe von cystein proteasen
US7399765B2 (en) * 2003-09-19 2008-07-15 Abbott Laboratories Substituted diazabicycloalkane derivatives
SE0400022D0 (sv) * 2004-01-08 2004-01-08 Medivir Ab New compounds
BRPI0506719A (pt) * 2004-01-08 2007-05-02 Medivir Ab composto, composição farmacêutica, e, uso de um composto
JP2005350417A (ja) * 2004-06-11 2005-12-22 Dai Ichi Seiyaku Co Ltd 還元的エーテル化法を用いたピロリジン誘導体の製造法
US7488848B2 (en) * 2005-03-21 2009-02-10 Virobay, Inc. Alpha ketoamide compounds as cysteine protease inhibitors
GB0513840D0 (en) * 2005-07-07 2005-08-10 Medivir Ab Cysteine protease inhibitors
GB0513839D0 (en) * 2005-07-07 2005-08-10 Medivir Ab Cysteine protease inhibitors
GB0614073D0 (en) 2006-07-14 2006-08-23 Amura Therapeutics Ltd Compounds
GB0614042D0 (en) 2006-07-14 2006-08-23 Amura Therapeutics Ltd Compounds
GB0614046D0 (en) 2006-07-14 2006-08-23 Amura Therapeutics Ltd Compounds
GB0614037D0 (en) * 2006-07-14 2006-08-23 Amura Therapeutics Ltd Compounds
GB0614053D0 (en) * 2006-07-14 2006-08-23 Amura Therapeutics Ltd Compounds
GB0614044D0 (en) * 2006-07-14 2006-08-23 Amura Therapeutics Ltd Compounds
GB0614052D0 (en) * 2006-07-14 2006-08-23 Amura Therapeutics Ltd Compounds
WO2008114054A1 (en) * 2007-03-19 2008-09-25 Medivir Ab Protease inhibitors
US7893067B2 (en) * 2007-06-27 2011-02-22 Medivir Ab Cysteine protease inhibitors
EP2719700A1 (en) 2008-01-09 2014-04-16 Amura Therapeutics Limited Tetrahydrofuro(3,2-b)pyrrol-3-one derivatives as inhibitors of cysteine proteinases
GB0804701D0 (en) 2008-03-13 2008-04-16 Amura Therapeutics Ltd Compounds
GB0804702D0 (en) * 2008-03-13 2008-04-16 Amura Therapeutics Ltd Compounds
US9409880B2 (en) 2011-01-20 2016-08-09 The Regents Of The University Of Colorado, A Body Corporate Modulators of TLR3/dsRNA complex and uses thereof
PT2891492T (pt) * 2012-08-30 2022-12-13 Univ Tokyo Agente de controlo de endoparasitas
CN106279188A (zh) * 2016-07-21 2017-01-04 青岛科技大学 一种多取代呋喃并[2,3‑b]吡咯衍生物的制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998050533A1 (en) * 1997-05-06 1998-11-12 Smithkline Beecham Corporation Protease inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3652574A (en) * 1970-04-01 1972-03-28 Abbott Lab Certain 1 2 3 4 - tetrahydro-5h-pyrido (4 3-b)indoles and the corresponding 1 2 3 4-tetrahydro-9h-pyrido(3 4-b)indoles and derivatives thereof
DE3601226A1 (de) * 1986-01-17 1987-07-23 Bayer Ag Dihydropyridinlactole, verfahren zur herstellung und ihre verwendung in arzneimitteln
RU2137768C1 (ru) * 1993-12-15 1999-09-20 Мерк энд Ко, Инк. Ингибиторы hiv протеазы
DZ2285A1 (fr) 1996-08-08 2002-12-25 Smithkline Beecham Corp Inhibiteurs de protéase de la cystéine.
EP0923535A4 (en) 1996-08-28 2001-01-10 Smithkline Beecham Corp CYSTEINE PROTEASE INHIBITORS
EA002100B1 (ru) 1996-12-23 2001-12-24 Элан Фармасьютикалз, Инк. ЦИКЛОАЛКИЛЬНЫЕ СОЕДИНЕНИЯ, ЛАКТАМЫ, ЛАКТОНЫ И РОДСТВЕННЫЕ СОЕДИНЕНИЯ, СОДЕРЖАЩИЕ ИХ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ И СПОСОБЫ ИНГИБИРОВАНИЯ ВЫСВОБОЖДЕНИЯ И/ИЛИ СИНТЕЗА β-АМИЛОИДНОГО ПЕПТИДА С ПОМОЩЬЮ УКАЗАННЫХ СОЕДИНЕНИЙ
MA26618A1 (fr) 1998-04-09 2004-12-20 Smithkline Beecham Corp Composes et compositions pharmaceutiques pour le traitement du paludisme
CO5150165A1 (es) 1998-11-13 2002-04-29 Smithkline Beecham Plc Inhibidores de proteasa: tipo catepsina k
GB9911417D0 (en) * 1999-05-18 1999-07-14 Peptide Therapeutics Ltd Furanone derivatives as inhibitors of cathepsin s
JP2004513942A (ja) 2000-11-17 2004-05-13 メディヴァー　ユーケイ　リミテッド システインプロテアーゼインヒビター
JP2004523506A (ja) 2000-12-22 2004-08-05 アクシス・ファーマシューティカルズ・インコーポレイテッド カテプシン阻害剤としての新規な化合物と組成物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998050533A1 (en) * 1997-05-06 1998-11-12 Smithkline Beecham Corporation Protease inhibitors

Also Published As

Publication number Publication date
CN1269822C (zh) 2006-08-16
JP2004518674A (ja) 2004-06-24
AU2002219397B2 (en) 2008-02-14
CA2436462A1 (en) 2002-07-25
EP1362052A1 (en) 2003-11-19
HK1060729A1 (en) 2004-08-20
BR0206501A (pt) 2004-01-13
RU2329266C2 (ru) 2008-07-20
CN1486320A (zh) 2004-03-31
NO20033220L (no) 2003-09-17
DK1362052T3 (da) 2007-07-09
WO2002057270A1 (en) 2002-07-25
US7425562B2 (en) 2008-09-16
EP1362052B1 (en) 2007-03-07
CA2436462C (en) 2011-07-05
IL156774A0 (en) 2004-02-08
MXPA03006224A (es) 2004-10-15
US20040138250A1 (en) 2004-07-15
CY1106640T1 (el) 2012-01-25
NZ526913A (en) 2004-12-24
NO328208B1 (no) 2010-01-11
JP4608183B2 (ja) 2011-01-05
IL156774A (en) 2008-08-07
NO20033220D0 (no) 2003-07-16
DE60218633D1 (de) 2007-04-19
ES2281516T3 (es) 2007-10-01
ATE356130T1 (de) 2007-03-15
DE60218633T2 (de) 2008-02-21
KR20030075161A (ko) 2003-09-22
PT1362052E (pt) 2007-04-30
US20090247471A1 (en) 2009-10-01
RU2003125270A (ru) 2005-02-20

Similar Documents

Publication Publication Date Title
KR100860067B1 (ko) 크루지페인 및 기타 시스테인 프로테아제의 억제제
AU2002219397A1 (en) Inhibitors of cruzipain and other cysteine proteases
WO2008007107A1 (en) Tetrahydrofuro (3, 2-b) pyrrol-3-one derivatives as inhibitors of cysteine proteinases
US6958358B2 (en) Inhibitors of cruzipain and other cysteine proteases
US8053437B2 (en) Furo[3. 2-B] pyrrol derivatives
EP1362042A1 (en) Cyclic 2-carbonylaminoketones as inhibitors of cruzipain and other cysteine proteases
US20040127424A1 (en) Inhibitors of cruzipain and other cysteine proteases
US20090131502A1 (en) Biologically active compounds
US7846934B2 (en) Furo[3,2-B] pyrrol-3-one derivatives and their use as cysteinyl proteinase inhibitors
EP2046795A1 (en) Furo[3,2-b]pyrrol-3-one derivatives and their use as cysteinyl proteinase inhibitors
AU2002225157A1 (en) Inhibitors of cruzipain and other cysteine proteases
WO2008007112A1 (en) Tetrahydrofuro [3, 2-b] pyrr0l-3-ones as cathepsin k inhibitors
US20040127549A1 (en) Cyclic 2-carbonylaminoketones as inhibitors of cruzipain and other cysteine proteases
BRPI0206501B1 (pt) An inhibitor compound of cruzipain and other cysteine ​​proteases, their uses, their pharmaceutical or veterinary composition, the process for the preparation of said composition and the method of establishing whether a cysteine ​​protease contributes to a biochemical function
AU2002219399A1 (en) Cyclic 2-carbonylaminoketones as inhibitors of cruzipain and other cysteine proteases

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

St.27 status event code: A-3-3-V10-V11-apl-PJ0201

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PB0901 Examination by re-examination before a trial

St.27 status event code: A-6-3-E10-E12-rex-PB0901

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

St.27 status event code: A-3-4-F10-F13-rex-PB0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20120914

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 20130905

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

FPAY Annual fee payment

Payment date: 20141020

Year of fee payment: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

FPAY Annual fee payment

Payment date: 20150819

Year of fee payment: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

FPAY Annual fee payment

Payment date: 20160818

Year of fee payment: 9

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

FPAY Annual fee payment

Payment date: 20170818

Year of fee payment: 10

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 10

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20180919

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20180919